ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "neuropsychiatric disorders"

  • Abstract Number: 0550 • ACR Convergence 2023

    Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus

    Nursen Cetrez1, Julius Lindblom1, Raffaele Da Mutten2, Dionysis Nikolopoulos2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden

    Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is linked to increased morbidity, mortality, and adverse health-related quality of life. Early disease, a history of NPSLE, aPL…
  • Abstract Number: 0570 • ACR Convergence 2023

    BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations

    Ana Carolina Alencar1, Taís Mazzola1, Samara Sepresse1, Bruna Aquino1, Isadora Teixeira1, Isadora Ribeiro1, Liara Rizzi1, Ítalo Aventurato1, Marjorie Da Silva1, Marcio Balthazar1, Lilian Costallat1, Roberto Marini2, Luciana Silva1, Clarissa Yasuda1, Fernando Cendes1, Timothy Niewold3 and Simone Appenzeller1, 1UNICAMP, Campinas, Brazil, 2Revista Brasileira de Reumatologia, Campinas, Brazil, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Autoantibodies and auto reactive B cells participate on the pathogenesis of systemic lupus erythematosus (SLE), affecting various organs and tissues, including the nervous system,…
  • Abstract Number: 0890 • ACR Convergence 2023

    Specificity of Brain-Intrinsic and Hematopoietic-Derived Mechanisms in Mediating Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

    Hadijat Makinde, Yidan Wang, Stumpf Cecilia and Carla Cuda, Northwestern University, Chicago, IL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple end organs including the brain. Despite a prevalence of over 50% in…
  • Abstract Number: 0895 • ACR Convergence 2023

    Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus

    Chaim Putterman1, Elise Mike2 and Sayra Garcia1, 1Albert Einstein College of Medicine, Bronx, NY, 2Johns Hopkins, Bronx, NY

    Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…
  • Abstract Number: 1234 • ACR Convergence 2023

    Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity

    Jaqueline de amorim1, Simone Kishimoto1, Paula Fernandes1, Roberto Marini2, Zahi Touma3, Hermine Brunner4 and Simone Appenzeller1, 1UNICAMP, Campinas, Brazil, 2Revista Brasileira de Reumatologia, Campinas, Brazil, 3University of Toronto, Toronto, ON, Canada, 4Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH

    Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
  • Abstract Number: 1460 • ACR Convergence 2023

    Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus

    Dionysis Nikolopoulos1, Nursen Cetrez2, Julius Lindblom2 and Ioannis Parodis2, 1Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Substantial proportions of systemic lupus erythematosus (SLE) patients report severe fatigue and adverse Health-related Quality of Life (HRQoL). Particularly neuropsychiatric manifestations have been associated…
  • Abstract Number: 1473 • ACR Convergence 2023

    Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades

    Ansaam Daoud1, Loai Dweik2, Marina Nighat Magrey3 and Omer Pamuk4, 1University Hospitals, Case Western Reserve University, Akron, OH, 2Cleveland Clinic Akron General, Akron, OH, 3Case Western Reserve University, University Hospitals, Cleveland, OH, 4University Hospitals Cleveland Medical Center, Cleveland, OH

    Background/Purpose: SLE is a chronic autoimmune disease and affects many organ systems. Juvenile onset disease, male sex, renal involvement, and central nervous system involvement are…
  • Abstract Number: 1478 • ACR Convergence 2023

    Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review

    Alain Sanchez-Rodriguez1, Mariana Gonzalez-Treviño1, Hannah Langenfeld2, Cynthia Crowson3, Maria Valenzuela-Almada4, Alejandro Rabinstein5, Larry J. Prokop6, Isabel Valenzuela-Almada7 and Ali Duarte-Garcia3, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Department of Pediatrics, Children’s National Medical Center, Washington, DC, 5Department of Neurology, Mayo Clinic, Rochester, MN, 6Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, 7Division of Internal Medicine, Hospital Medica Sur, Mexico City, Mexico

    Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with SLE and Posterior reversible encephalopathy syndrome (PRES). Methods: We performed a multicenter cohort…
  • Abstract Number: 1601 • ACR Convergence 2023

    Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus

    Joshua Reynolds1, Lola Torz2, Natalia Petersen2, Ayal Ben-Zvi3 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2Novo Nordic, Global Obesity Research, Malov, Denmark, 3Hebrew University of Jerusalem, Jerusalem, Israel

    Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…
  • Abstract Number: 1625 • ACR Convergence 2023

    Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning

    santiago arciniegas1, Matthias W. Wagner2, Logi Vidarsson2, Birgit Ertl-Wagner2, Tala El Tal3, Asha Jeyanathan2, Lawrence Ng2, Linda Hiraki2, Deborah Levy2, George M. Ibrahim2 and Andrea Knight2, 1University of Toronto, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
  • Abstract Number: 2056 • ACR Convergence 2023

    Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases

    Meiqian Ma1, Erin Masteron2 and Jennifer Frankovich1, 1Stanford University School of Medicine, Palo Alto, CA, 2University of Washington School of Public Health, Seattle, WA

    Background/Purpose: Certain psychiatric conditions are associated with systemic inflammatory processes. We aimed to evaluate whether a pediatric condition characterized by a sudden onset of severe…
  • Abstract Number: 2303 • ACR Convergence 2023

    Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?

    Jaime Vondenberg1, Chao Zhang1 and Emily Littlejohn2, 1Cleveland Clinic Foundation, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…
  • Abstract Number: 041 • 2023 Pediatric Rheumatology Symposium

    Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort

    Jaqueline De Amorim1, Simone Kishimoto1, Paula Fernandes1, Roberto Marini1, Lilian Costallat1, Zahi Touma2, Hermine Brunner3 and Simone Appenzelle4, 1UNICAMP, São Paulo, Brazil, 2University of Toronto, Toronto, ON, Canada, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4University of Campinas, Campinas, Sao Paulo, Brazil

    Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…
  • Abstract Number: 2223 • ACR Convergence 2022

    Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus

    Julius Lindblom1, Daniel Toro-Domínguez2, Elena Carnero-Montoro2, Maria Orietta Borghi3, Jessica Castillo4, Ellen Iacobaeus1, Yvonne Enman5, Chandra Mohan4, Marta Alarcon-Riquelme2, Guillermo Barturen2 and Ioannis Parodis1, 1Karolinska Institutet, Stockholm, Sweden, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, 4University of Houston, Houston, TX, 5Karolinska Institutet, Sundbyberg, Sweden

    Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
  • Abstract Number: 2265 • ACR Convergence 2022

    Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus

    Henri Tiedge1, ILHAM MUSLIMOV2, Valerio Berardi2, Stacy Stephenson3, Ellen M. Ginzler4, Anca Askanase5 and John Hanly6, 1SUNY, Downstate Medical Center, Brooklyn, NY, 2SUNY Downstate Medical Center, Brooklyn, NY, 3SUNY Downstate Medical Center, dep. of Comparative Medicine, Brooklyn, NY, 4SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 5Columbia University Medical Center, New York, NY, 6Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada

    Background/Purpose: Neuropsychiatric (NP) involvement is common in systemic lupus erythematosus (SLE). Manifestations often include seizures and cognitive impairment but underlying etiology remains poorly understood. Brain…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology